Literature DB >> 1653157

Aldose reductase inhibition with imirestat-effects on impulse conduction and insulin-stimulation of Na+/K(+)-adenosine triphosphatase activity in sciatic nerves of streptozotocin-diabetic rats.

A L Carrington1, C B Ettlinger, N A Calcutt, D R Tomlinson.   

Abstract

This study describes reduced motor nerve conduction velocity and increased resistance to hypoxia-induced conduction failure in sciatic nerves of rats after four weeks of streptozotocin-induced diabetes (both effects were significant at p less than 0.05). These changes occurred in the absence of any deficit in the steady-state ouabain-sensitive adenosine triphosphatase (ATPase) activity of sciatic nerve endoneurial homogenates. The addition of 10 nmol/l insulin to endoneurial homogenates from control animals resulted in a 34% increase in ouabain-sensitive ATPase activity and a 19% reduction in ouabain-insensitive ATPase activity (both p less than 0.01). This stimulation of ouabain-sensitive ATPase activity by insulin did not occur in homogenates from diabetic rats. Treating diabetic rats daily with the aldose reductase inhibitor, imirestat (1 mg/kg) improved nerve conduction velocity (p less than 0.05) but was without effect upon the resistance to hypoxic conduction blockade or the deficit in insulin-stimulated ouabain-sensitive ATPase activity. These data suggest that in streptozotocin-diabetic rats the functional disorders of reduced motor nerve conduction velocity and increased resistance to hypoxic conduction blockade do not share a common aetiology and that impaired nerve conduction is not related to reduced maximal potential ouabain-sensitive ATPase activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1653157     DOI: 10.1007/bf00403177

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  27 in total

1.  Improvement in nerve conduction following treatment in newly diagnosed diabetics.

Authors:  J D Ward; C G Barnes; D J Fisher; J D Jessop; R W Baker
Journal:  Lancet       Date:  1971-02-27       Impact factor: 79.321

2.  Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats.

Authors:  J H Mayer; D R Tomlinson
Journal:  Diabetologia       Date:  1983-11       Impact factor: 10.122

3.  Reversal, by treatment with an aldose reductase inhibitor, of impaired axonal transport and motor nerve conduction velocity in experimental diabetes mellitus.

Authors:  D R Tomlinson; P R Holmes; J H Mayer
Journal:  Neurosci Lett       Date:  1982-08-16       Impact factor: 3.046

4.  Does galactose feeding provide a valid model of consequences of exaggerated polyol-pathway flux in peripheral nerve in experimental diabetes?

Authors:  G B Willars; J E Lambourne; D R Tomlinson
Journal:  Diabetes       Date:  1987-12       Impact factor: 9.461

5.  The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats.

Authors:  D K Yue; M A Hanwell; P M Satchell; J R Turtle
Journal:  Diabetes       Date:  1982-09       Impact factor: 9.461

6.  Ischemic conduction failure and energy metabolism in experimental diabetic neuropathy.

Authors:  P A Low; K Ward; J D Schmelzer; S Brimijoin
Journal:  Am J Physiol       Date:  1985-04

7.  Impaired rat sciatic nerve sodium-potassium adenosine triphosphatase in acute streptozocin diabetes and its correction by dietary myo-inositol supplementation.

Authors:  D A Greene; S A Lattimer
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

8.  Resistance of the diabetic rat nerve to ischemic inactivation.

Authors:  J Jaramillo; N Simard-Duquesne; D Dvornik
Journal:  Can J Physiol Pharmacol       Date:  1985-07       Impact factor: 2.273

9.  Adenosine triphosphatase in nerves and ganglia of rats with streptozotocin-induced diabetes or galactosaemia; effects of aldose reductase inhibition.

Authors:  J E Lambourne; A M Brown; N Calcutt; D R Tomlinson; G B Willars
Journal:  Diabetologia       Date:  1988-06       Impact factor: 10.122

10.  Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil.

Authors:  D R Tomlinson; R J Moriarty; J H Mayer
Journal:  Diabetes       Date:  1984-05       Impact factor: 9.461

View more
  6 in total

1.  Pharmacological manipulation of vascular endothelium function in non-diabetic and streptozotocin-diabetic rats: effects on nerve conduction, hypoxic resistance and endoneurial capillarization.

Authors:  N E Cameron; M A Cotter; K C Dines; E K Maxfield
Journal:  Diabetologia       Date:  1993-06       Impact factor: 10.122

2.  Nerve ischaemia in diabetic rats: time-course of development, effect of insulin treatment plus comparison of streptozotocin and BB models.

Authors:  E J Stevens; A L Carrington; D R Tomlinson
Journal:  Diabetologia       Date:  1994-01       Impact factor: 10.122

3.  Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats.

Authors:  N E Cameron; M A Cotter; K Dines; A Love
Journal:  Diabetologia       Date:  1992-10       Impact factor: 10.122

4.  Dissociation between biochemical and functional effects of the aldose reductase inhibitor, ponalrestat, on peripheral nerve in diabetic rats.

Authors:  N E Cameron; M A Cotter
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

5.  The effects of aldose reductase inhibition with ponalrestat on changes in vascular function in streptozotocin diabetic rats.

Authors:  D J Otter; R Chess-Williams
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

6.  Alloxan-diabetes alters kinetic properties of the membrane-bound form, but not of the soluble form, of acetylcholinesterase in rat brain.

Authors:  M A Khandkar; E Mukherjee; D V Parmar; S S Katyare
Journal:  Biochem J       Date:  1995-05-01       Impact factor: 3.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.